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ABSTRACT
Objective: The objective was to improve the solubility and dissolution of ivacaftor tablets by using solid dispersion (SD) technique.
Methods: Ivacaftor is practically insoluble (<0.001 mg/mL) over pH value of 3.0–7.5 due to low solubility, and it shows poor bioavailability after 
oral administration. Therefore, SDs of Ivacaftor were prepared by SD technique of hot-melt extrusion (HME) by adding different polymers such as 
Soluplus, Hypromellose 5 cps, and Copovidone with surfactants sodium lauryl sulfate, poloxamer, and polysorbate 80 to enhance its solubility.
Results: The analysis of X-ray diffraction and differential scanning calorimetry of Solid dispersion by HME represents the polymorphic conversion 
of ivacaftor from crystalline structure form to an amorphous structure form. The results show that the formulation of Ivacaftor SDs by HMT has 
enhanced the solubility and dissolution of Ivacaftor.
Conclusion: In the present study, the SDs of the poorly soluble drug substance Ivacaftor were successfully prepared using HME. The in vitro dissolution 
test shows a significant increase in dissolution rate of SDs prepared by HME (95%) in formulation FHM8 compared with plain Ivacaftor (9%) within 
30 min.
Keywords: Ivacaftor, Solid dispersion, Hot-melt extrusion, Soluplus, Copovidone, Hypromellose 5 cps, Sodium lauryl sulfate, Poloxamer and 
polysorbate 80.
INTRODUCTION
For absorption of oral formulations, solubility and permeability 
are act as two major factors. Nowadays, some of the new chemical 
entities are poor water solubility drugs. Therefore, improving the 
drug bioavailability is the most tough challenge of solid oral dosage 
formulations. Solid dispersion is one of the most successful technologies 
to enhance the solubility of drug. In this approach, drug is converted 
its polymorphic form by emerged with inert carrier. The conversion of 
amorphous form drug can easily contact with dissolution media and 
become more solubility and bioavailability [1-3].
The process of hot melt extrusion (HME) is one of the solid dispersion 
(SD) technique that efficient mixing of drug with polymer and inert 
excipient, progressive melting and finally solidified. The drug-
polymer ratio, quantity of surfactant, selection of polymer, extrusion 
temperature, and screw rotation speed are important parameters; it 
can affect quality and solubility of drug product. For example, the screw 
rotation speed may impact the proper conversion of polymorphic form 
and mixing of polymer and surfactant [4,5].
Fig 1, represents Chemical structure of Ivacaftor is a cystic fibrosis 
transmembrane conductance regulator potentiator indicated for the 
treatment of cystic fibrosis. Ivacaftor is a white to off-white crystalline 
powder. The crystalline form of the drug substances is practically 
insoluble in aqueous media (<0.001 mg/ml). To increase the solubility 
of Ivacaftor, HME technology was selected. Therefore, the selection of 
polymer carrier able to conversion of polymorphic form of ivacaftor, 
along with effects keeping ivacaftor in amorphous state [6,7].
The present study was carried out to develop Ivacaftor SD by HME 
(Fig. 2). Technology using three different polymers and three different 
surfactants of enhancing drug solubility. By different prototype 
formulations select one optimize formulation based on dissolution 
profile and perform factorial design.
MATERIALS AND METHODS
Materials
Ivacaftor drug substance was gift sample of Aurobindo pharma Ltd., 
Hyderabad, India. Cellulose microcrystalline (Avicel pH 102) was gifted 
by FMC Biopolymer, USA. Hypromellose 5 cps was gift sample of Dow 
Chemical, USA. Aerosil 200 (colloidal silicon dioxide) was gifted by Evonik, 
Germany. Polyvinyl acetate–polyvinyl caprolactam–polyethylene glycol 
graft copolymer, grade Soluplus and Copovidone, sodium lauryl sulfate, 
and poloxamer were gift sample of BASF, and polysorbate 80 was gifted 
by Seppic. Croscarmellose sodium was gifted by DFE Pharma, Germany, 
and magnesium stearate was given by Peter Greven, the Netherlands.
HME
Preparation of Ivacaftor SDs by HME
Ivacaftor SD was prepared by different carriers such as Copovidone, 
Soluplus, and Hypromellose 5 cps along with surfactants such as sodium 
lauryl sulfate, poloxamer, and polysorbate 80. HME Pharma 24 - Thermo 
Fisher twin screw model was used for the preparation of SDs using feed 
rate of 1–1.3 Kg/h, torque: 4 Barr, and 10 different temperature zones 
from 20°±2°C to 210°±2°C with chillers zone maintain at temperature 
2–5°C (where melt was converted into flake pieces).
Manufacturing process
•	 Step	1: Ivacaftor was taken with Copovidone (one set of trials), 
Hypromellose 5 cps (second set of trials), and Soluplus (third set of 
trials) along with surfactants such as sodium lauryl sulfate, poloxamer. 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i1.30369
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and polysorbate 80 which were sifted through #40 mesh and mixed 
well using poly bag for 10 min. Polysorbate 80 is available in liquid state 
so dilute with water as 10% solids and coating into plain Ivacaftor API 
by using FBP. The above material was hot-melt extruded using above 
mentioned at different temperature zones (Table 1). Table 2, represents 
composition of Ivacaftor by HME. The extrudes were transparent in 
FHM2, FHM3, FHM5, FHM6, FHM8, and FHM9. Remaining extrudes 
were opaque in nature. The extrudes crushed into mortar and pestle. 
The powder was granular in nature and sifted through #30 mesh.
•	 Step	2:	The	extrudes	of	step	no	1,	cellulose	microcrystalline	(Avicel	
pH 102), croscarmellose sodium (Ac-Di-Sol), and colloidal silicon 
dioxide (Aerosil 200) were sifted through #30 mesh and mixed well 
using poly bag for 10 min.
•	 Step	3:	Magnesium	stearate	sifted	through	#40	mesh	and	added	to	
step no 2 mixed in poly bag for 5 min manually.
•	 Step	4:	The	 lubricated	blend	of	 step	no	3	was	compressed	using	
12.00 mm round-shaped punches.
Evaluation of Ivacaftor SDs
Solubility studies of Ivacaftor SDs
Solubility measurements of Ivacaftor were performed with solvent 
shaken for the 12 h at room temperature. Subsequently, the suspensions 
were filtered through a Whatman filter paper. A filtered solution of 
Ivacaftor was analyzed using UV 255 nm.
Drug content
Solid dispersions equivalent to 150 mg of Ivacaftor were weighed 
accurately and dissolved in 100 ml of 0.1% trifluoroacetic 
acid: acetonitrile (20:80 ratio). The solution was filtered and diluted 
with the suitable amount, and drug content was analyzed at ëmax255 nm 
against blank using UV spectrometer [8]. The actual drug content was 
calculated using the following equation:
Actual amount of drug in solid dispersion%Drug content = ×100
Theoretical amount of drug in solid dispersion
In vitro drug release studies
The in vitro drug release profile for each SD as well as plain drug 
was performed using USP type 2 dissolution apparatus. The sample 
equivalent to 150 mg of Ivacaftor was added and the conditions 
maintained are shown in Table 3.
The samples were drawn at specified time intervals, and the obtained 
samples were analyzed using UV-visible spectrophotometer at 255 nm. 
The cumulative percentage release was calculated [9].
RESULTS AND DISCUSSION
Fourier-transform infrared (FT-IR) spectrometry studies
FT-IR spectrum majorly was used to determine if any of interaction 
between the drug and excipient used. The prominent peaks of Ivacaftor 
were observed (Fig. 3) the region: 3332 cm−1 due to >N-H (N-H 
stretching), 2957 cm−1 due to –O-H (-OH stretching), and 1647 cm−1 due 
to –C=O (stretch). The optimized formulation FSD8 (Fig. 4) displayed the 
characteristic peaks at wave numbers nearer to that of plain Ivacaftor 
(Fig. 3). Overall, there was no alteration in the characteristic peaks of 
the optimized formulation, suggesting that there was no interaction 
between the drug and polymers.
Differential scanning calorimetry (DSC)
The DSC thermogram of plain Ivacaftor is shown in Fig. 5, sharp 
peak of endothermic at 205°C melting point, indicating that the drug 
was crystalline. The absence of peaks in the SD of formulation FHM8 
(Ivacaftor: Soluplus (1:1) with poloxamer) indicates that the drug was 
converted in amorphous form [10].
Table 1: Temperatures to be monitored during HME process
















Maintained at temperature 2–5°C  
(where melt was converted into pieces of flakes)
HME: Hot-melt extrusion
Fig. 1: Chemical structure of Ivacaftor
Table 2: Composition of Ivacaftor SDs by HME
S. No Ingredients (Units) FHM1 FHM2 FHM3 FHM4 FHM5 FHM6 FHM7 FHM8 FHM9
1. Ivacaftor (mg) 150.0 150.0 150.0 150.0 150.0 150.0 150.0 150.0 150.0
2. Copovidone (mg) 150.0 150.0 150.0 - - - - - -
3. Hypromellose 5 cps (mg) - - - 150.0 150.0 150.0 - - -
4. Soluplus (mg) - - - - - - 150.0 150.0 150.0
5. Sodium lauryl sulfate (mg) 15.0 - - 15.0 - - 15.0 - -
6. Poloxamer (mg) - 15.0 - - 15.0 - - 15.0 -
7. Polysorbate 80 (mg) - - 15.0 - - 15.0 - - 15.0
Total quantity of HME material weight (mg) 315.0 315.0 315.0 315.0 315.0 315.0 315.0 315.0 315.0
8. Microcrystalline cellulose (Avicel pH 102) (mg) 214.5 214.5 214.5 214.5 214.5 214.5 214.5 214.5 214.5
9. Croscarmellose sodium (Ac-Di-Sol) (mg) 12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5
10. Colloidal silicon dioxide (Aerosil 200) (mg) 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0
11. Magnesium stearate (mg) 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0
Total tablet weight (mg) 550.0 550.0 550.0 550.0 550.0 550.0 550.0 550.0 550.0
HME: Hot-melt extrusion, SD: Solid dispersions
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X-ray diffraction (XRD) analysis
The XRD of Ivacaftor observed that multiple sharp peaks (Fig. 6) indicates 
that the drug was in crystalline nature. SD optimized formulation FHM8 
(Ivacaftor: Soluplus (1:1) with poloxamer) when exposed to X-ray 
beam observed no crystalline endothermic peaks and characteristic 
intensities of Ivacaftor (Fig. 7). This indicates that complete conversion 
of crystalline Ivacaftor into amorphous polymorphic state during hot 
melt extrusion process. From the XRD studies, it is clearly confirmed 
that HME of batch no FHM8 drug substance converted into amorphous 
form [11].
Scanning electron microscopy (SEM)
HMEs of FHM8 performed surface micrographs, and plain Ivacaftor was 
determined into SEM technique. The SEM micrograph of plain Ivacaftor 
Fig. 2: Schematic diagram of hot-melt extrusion
Fig. 3: Fourier-transform infrared spectra of plain drug
Fig. 4: Fourier-transform infrared spectra of formulation FSD8 solid dispersion
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Evaluation parameters
Solubility studies of Ivacaftor SDs
Nine formulations of the SDs were prepared using HME technique 
with respective polymer. After preparation of SDs using HME process, 
the resulting extruded mixture was analyzed for solubility of drug 
and was compared with plain drug itself (Table 4). The formulation 
of (Ivacaftor: soluplus (1:1) with poloxamer) FHM8 represents the 
solubility enhancement as compared to plain drug (plain drug solubility 
is 0.001 mg/ml) [14,15].
In vitro dissolution studies
The obtained drug release data for formulations FHM1 to FHM9 
are shows in Fig 9. Table 6 shows the cumulative percentage drug 
released for all formulations. Cumulative percentage of drug released 
after 30 min was 72%, 77%, 78%, 80%, 85%, 82%, 89%, 95%, and 
93% for FHM1–FHM9, respectively, and was 9% in 30 min for plain 
drug. In vitro studies reveal that there is a marked increase in the 
dissolution rate of Ivacaftor from all the SDs when compared to plain 
drug itself. From the in vitro drug release profiles, formulation FHM8 
containing Ivacaftor: Soluplus (1:1) with surfactant poloxamer was best 
formulation which shows high dissolution rate, i.e., 95.0% compared 
with other formulations. This may attributed to increase the conversion 
of drug to amorphous (Table 5).
The dissolution profiles of Ivacaftor SDs prepared by HME (FHM8) 
shown that the % drug release was more compared with all nine 
formulations. The SD formulations by FHM8 shown highest drug 
release, i.e., 95.0%, respectively, after 30 min, where plain drug release 
was only 9%.
Statistical analysis
Based on the preliminary feasibility study, a design of experiments 
(DOE) with full factorial design (Table 7) was performed to optimize 
Soluplus and poloxamer concentrations used in the formulation. 
Percentage of drug release in 30 min was identified as a critical 
Fig. 5: Differential scanning calorimetry thermograms of plain drug and optimized formulation FHM8
Fig. 6: Powder X-ray diffraction patterns of Ivacaftor plain drug
Table 3: In vitro dissolution studies of test parameters




pH 6.8 sodium phosphate buffer with 0.7% 
sodium dodecyl sulfate
Apparatus USP apparatus II (paddle type) with sinker
Temperature 37±0.5°C
RPM 65
Volume of medium 900 ml
Sampling intervals 5, 10, 15, 20, and 30 min
Sample volume 10 ml withdrawn and replaced with 10 ml of 
dissolution medium
Table 4: Solubility in aqueous media and drug content of SDs 
prepared by HME method
S. No. Formulation Solubility (mg/ml) % Drug content
1 Plain drug 0.001 -
2 FHM8 0.25 98.5%
HME: Hot-melt extrusion, SD: Solid dispersions
Fig. 7: Powder X-ray diffraction patterns of the optimized 
formulation of FHM8
(Fig. 8) was observed crystalline drug agglomerates with ordered 
shape and size (Fig. 8). The surface characteristics extrude of optimized 
formulation FHM8 [12,13].
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quality attribute of the formulation composition and the ranges for the 
responses were based on the dissolution of the formulations, and it 
summarizes the study design and acceptance criteria. Hence, the drug 
release at 30 min using USP apparatus II (Paddle) at 65 rpm in pH 6.8 
sodium phosphate buffer with 0.7% sodium dodecyl sulfate, 900 mL, 
was also evaluated.
A constant tablet weight of 550.00 mg was used by compensating the 
quantity with the diluent (Microcrystalline cellulose [Avicel pH 102]) 
to achieve the target weight. The goal of formulation development was 
to select the optimize Soluplus and poloxamer concentrations and to 
understand if there was any interaction within the variables. This study 
also sought to establish the robustness of the proposed formulation. 
Initially, 22 full factorial DOE with one center points was studied, and from 
the results of the formulation trails using Design-Expert® 11 Software, the 
table no 8 ,  summarizes the factors as soluplus, poloxamer  and responses 
as dissolution in 30 min studied for subjected to dissolution testing.
The experimental results for dissolution (Y1) are presented in Table 8.
Fig 10, represents the % drug release of optimum batch (FHM8) and 
DOE trial batches. Using different concentrations of Soluplus shows 
major effect of dissolution profile. By using soluplus concentration 75 
mg shows the significant effect on dissolution profile and using 150 
mg, 225 mg represents no significant effect on dissolution. There is 
Table 5: Physicochemical characteristics of Ivacaftor SD tablets
Batch number Weight of tablet (mg) Thickness (mm) Friability test (<1%) Hardness (KP) Disintegration (Sec)
FHM1 550±4 6.6±0.2 0.12 8±1 55
FHM2 550±3 6.5±0.2 0.08 8±2 48
FHM3 550±3 6.5±0.2 0.06 8±1 40
FHM4 550±4 6.6±0.1 0.13 8±2 52
FHM5 550±4 6.5±0.1 0.14 7±2 49
FHM6 550±4 6.5±0.2 0.09 8±1 48
FHM7 550±3 6.6±0.2 0.10 7±1 45
FHM8 550±3 6.6±0.1 0.08 8±1 42
FHM9 550±3 6.5±0.1 0.09 8±1 40
SD: Solid dispersions
Table 6: In vitro dissolution profile of plain drug and different formulations of Ivacaftor SDs (FHM1–FHM9)
Time (min) Cumulative % drug release
Plain drug FHM1 FHM2 FHM3 FHM4 FHM5 FHM6 FHM7 FHM8 FHM9
0 0 0 0 0 0 0 0 0 0 0
5 5 25 27 25 31 35 34 38 45 41
10 8 51 56 55 61 63 63 62 72 68
15 8 65 69 68 75 79 78 79 92 86
20 9 69 75 75 78 83 80 85 94 91
30 9 72 77 78 80 85 82 89 95 93
SDs: Solid dispersions





A: Soluplus 75 150 225
B: Poloxamer 7.5 15 22.5
Responses (min) Goal Acceptable ranges
Y1
Dissolution time Minimize Not<80% Q in 30 min
Fig. 8: Scanning electron microscopy images of Ivacaftor plain 
drug and extrudes of optimized formulation FHM8
Fig. 9: In vitro dissolution profiles of plain drug and hot-melt 
extrusion of ivacaftor tablets
Fig. 10: In vitro dissolution profiles of plain drug and hot-melt 
extrusion of Ivacaftor tablets
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no significant effect by using poloxamer at different concentrations on 
dissolution was observed. Poloxamer used in different concentrations 
from 7.5 to 22.5 shows no significant effect of formulation. So there is 
no much effect on dissolution by using poloxamer. (Table 9)
Table 8: Experimental results for dissolution (Y1)
S.No Factors : Formulation Variables Responses
Batch no A: Soluplus (mg) B: Poloxamer (mg) Y1: Dissolution in 30 min
1 FHM10 225 22.5 96
2 FHM11 225 7.5 94
3 FHM8 150 15 95
4 FHM12 75 22.5 47
5 FHM13 75 7.5 45
A two-factor experimental design represents p-value that shows a 
significant effect of the formulation. p<0.05 shows a significant effect 
and p>0.05 represents the non-significant effect. Data given in Table 10 
demonstrate that p=0.0103 which is <0.05 the selected model shows a 
Fig. 11: Half-normal plot
Fig. 12: Pareto chart
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significant effect. For Soluplus, p=0.00656 shows the significant effect 
by changing the concentration of Soluplus. For poloxamer p=0.126 
Fig. 13: Contour model plot
Fig. 14: Three-dimensional response surface plots
Table 9: Dissolution profiles of the formulations
Time (min) FHM8 FHM10 FHM11 FHM12 FHM13
Dissolution profile
5 45 48 47 19 18
10 72 75 72 37 35
15 92 93 91 42 42
20 94 94 93 45 45
30 95 96 94 47 45
which represents not significant effect by using different  poloxamer 
concentrations.
From the above half normal plot, the formulation variables on dissolution 
in 30 min shows that significant effect by using different concentrations of 
soluplus and poloxamer (Fig 12). Soluplus shows the longest effect in half-
normal plot and Pareto chart (Fig 11). Dissolution time in the formulation 
of the range studied is within the proposed specification limit (NLT 80% 
drug release in 30 min). Hence, in the present formulation, 150.0 mg per 
tablet of Soluplus and 15 mg poloxamer per tablet were selected for the 
finalized formulation.
Two-dimensional contour plots and three-dimensional response 
surface plots for variables are shown in Figs 13 and 14, respectively. 
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They were used to study the interaction effects of the independent 
factors on the responses at 1 time. The contour plot is formed by vertical 
axis and horizontal axis. The horizontal axis represents Soluplus and 
the vertical axis represents poloxamer.
CONCLUSION
In the present study, the SDs of the poorly soluble drug substance 
Ivacaftor were successfully prepared using HME. The in vitro dissolution 
test shows a significant increase in dissolution rate of SDs prepared by 
HME (95%) in formulation FHM8 compared with plain Ivacaftor (9%) 
within 30 min. The release of drug was slightly on the higher side at 
initial time points from Ivacaftor SD technique by hot-melt extrusion 
technique. The increase in dissolution rate of Ivacaftor is in order of SDs 
of HME > plain drug substance. DOE results show the significant effect 
using Soluplus. The mechanism involved in solubilization by improved 
wetting of drug substance by hydrophilic carriers represents rich with 
microenvironment formed at the surface of the drug substance which 
leads to improves dissolution rate. The crystallinity nature of drug 
substance was reduced in SD technique by formulation with polymers. 
The results from FT-IR concluded that there was no defined interaction 
between Ivacaftor and carriers. DSC and XRD results showed a 
conversion of crystal structure toward to amorphous form of Ivacaftor. 
Finally concluded that HMT  of Ivacaftor by using hydrophilic polymers 
would improved the aqueous dissolution rate, solubility and thereby 
enhance its systemic availability.
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